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Letter to the Editor
CD20+ T Cells in Primary Mediastinal Large B Cell Lymphoma Microenvironment
We have read the article entitled
“Evaluation of primary mediastinal
large B cell lymphoma by flow cyto-
metry” recently published in Cytometry
Part B with great interest (1). In this
article, Cherian and Fromm along with
neoplastic clone evaluated the reactive
infiltrate in primary mediastinal large B
cell lymphoma (PMLBCL). The authors
reported presence of CD3+CD4+CD7-
bright/CD45-bright subpopulation in
the reactive infiltrate in 41% of their
cases, which appears to be a common
finding in classical Hodgkin lymphoma
tumor microenvironment.
We observed CD20+ T cells in the
mediastinal mass tissue in two recent
cases with histologically proven
PMLBCL on flow cytometric analysis.
CD20+ T cells were identified by CD3,
CD7, and CD2 staining (Fig. 1). These
two cases with prominent CD20+ T cell
population (45.53% and 56.3% within
the CD45-bright lymphocyte gate)
showed decreased CD4/CD8 ratio
(0.49 and 0.35, respectively) in contrast
to the findings recently reported in
PMLBCL reactive tissue (1). In Case
1, the CD20 expression on T cells was
about the same intensity as that of
mature B cells and about one logarith-
mic difference lower than that of the
neoplastic cells, while in Case 2 the
CD20 expression on T cells was broad
compared to that of mature B cells
within the reactive infiltrate (Fig. 1A,
B). The specimen in Case 1 was run
and analyzed on Beckman Coulter
Epics XL flow cytometer (Brea, CA) on
three color panel and on Beckman
Coulter Gallios flow cytometer (Brea,
CA) on 10 color panel in Case 2. For
both panels, fluorescence minus one
controls were run to account for any
artifact or nonspecific fluorescence.
Three different fluorochrome conju-
gates of CD20 monoclonal antibody, all
with the same clone (Clone B9E9,
Beckman Coulter, Brea, CA) were used
in the panels—APC and APC Alexa
Fluor 750 in Case 1 and PE in Case 2.
Other B cell markers such as CD19
and CD22 were absent on these cells
suggesting that these were CD20-
expressing T cells and not B and T
cell–cell or cell particle–cell conjugates
(Fig. 1C). Ten-color flow cytometric
analysis of CD20+ T cells showed that
these were distributed among various
T cell subsets, including CD4−CD8−
(double-negative), CD4+CD8+ (double-
positive), CD8+, and CD4+ cells,
42.86%, 5.08%, 39.85%, and 12.22%,
respectively in Case 2. (Fig. 1D). Inter-
estingly, in the second case, there was
an increased double-negative T cell
presence (25% of T cells) with positive
TCR-γδ staining pattern (90%) in the
tumor microenvironment. To our
knowledge these findings have not
been reported in PMLBCL or any other
type of lymphoma reactive tissue.
A small population (~3–5%) of CD3
+CD20dim+ has been identified in
peripheral blood of healthy individ-
uals, cerebrospinal fluid, and primary
and secondary lymphoid tissue, includ-
ing thymus (2,3). It has been shown
that, immunophenotypically these T
cells are more common in CD8+,
CD45RO+ memory, and in CCR7− sub-
populations. Compared to CD3+CD20
− T cells, they show increased fre-
quency of IL-4, IL-17, IFN-γ, and tumor
necrosis factor (TNF)-α producing
cells (3).
Origin of these cells is controversial.
One study has suggested that these
cells may arise from transfer of CD20
molecules to T cells upon close T cell–
B cell interaction in the tissue by
intercellular exchange of membrane
components via a process known as
trogocytosis (4). However, another
study showed that peripheral blood
CD3+CD20+ cells transcribe both CD3
and CD20 (3).
The function of CD20+ T cells is not
yet clear. This subset has been found
to be in a higher state of activation in
patients with autoimmune disorders
such as psoriasis, rheumatoid arthritis,
multiple sclerosis, and increased in
ovarian cancer. Compared with healthy
individuals, circulating CD20+ T cells
have been shown to produce more
cytokines, interleukin IL-17A, TNF-α,
and IL-21 in patients with psoriasis.
Additionally, higher levels of IL-17A,
TNF-α, and IL-21 production by CD20+
T cells was observed in the affected
areas and skin lesions with increased
severity index scores in psoriasis (5).
In multiple sclerosis, activated CD20+
T cells have been shown in chronic
lesions of brain, secreting pro-
inflammatory cytokines IFN-γ and IL-
17, possibly contributing to the disease
pathogenesis (6). Eggleton and col-
leagues have reported that the propor-
tion of IL-17-producing CD20+ T cells
in the peripheral blood of rheumatoid
arthritis patients increased by 240-fold
as compared to healthy individuals (7).
In ovarian cancer, while CD20+ T cells
were 6% in peripheral blood, this pop-
ulation was found to be increased to
23% in ascites fluid (4).
Several cases of CD20+ T cell
leukemia/lymphoma have been reported
in the literature (8–13). Quintanilla-
Martinez et al. speculated that CD20+ T
cell lymphomas may arise from neo-
plastic transformation of normal CD20
+ T cell subset (8). In PMLBCL, it is
also possible that CD20+ T cells are
highly activated Th17 cells and may be
involved in antitumor immunity. Stud-
ies in larger number of cases analyzing
the tumor tissue and the effect of CD20
+ T cells in treatment outcome are
warranted, which might help guide
therapy including, the use of immuno-
therapy and immune checkpoint inhib-
itors, in particular (14).
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FIG. 1. Two cases of PMLBCL evaluated by flow cytometry. (A) Case 1 displaying CD20+ CD7+ T cells within the reactive infiltrate of the tumor tissue.
The CD20+ T cells have about same intensity of CD20 expression as that of mature B cells within the reactive infiltrate, while one log difference lower
CD20 intensity than that of neoplastic cells. (B) Case 2 displaying CD20+CD3+ T cells within the reactive infiltrate of the tumor tissue. The CD20+ T
cells show broad CD20 expression. Tumor cells were not detected in the tumor tissue specimen on the flow cytometric analysis. (C) CD20+ T cells in
Case 2 does not show any significant expression of other B cell markers such as CD19 and CD22. (D) CD20+ T cells in Case 2 showed that these cells
were distributed among various subsets of T cells, including CD4+, CD8+, CD4+CD8+ (double positive), and CD4−CD8− (double negative) T cells.
[Color figure can be viewed at wileyonlinelibrary.com]
CD20+ T CELLS IN PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA MICROENVIRONMENT 17
Cytometry Part B: Clinical Cytometry
lymphoma with aberrant expression of
CD79a and CD20: A diagnostic pitfall. Mod
Pathol. 2001;14:105–110.
13. Sun T, Akalin A, Rodacker M, Braun T.
CD20 positive T cell lymphoma: Is it a
real entity? J Clin Pathol. 2004;57(4):
442–444. https://doi.org/10.1136/jcp.2003.
011734.
14. Wright Z, Brown A. High-grade neutrope-
nia in a patient successfully treated with
nivolumab for refractory primary mediasti-
nal B-cell lymphoma. Blood Adv. 2017;1
(17):1306–1308.
Manisha Gadgeel,1





Hospital of Michigan, and Carman and
Ann Adams Department of Pediatrics,
Wayne State University, Detroit, Michigan
2Pediatric Bone Marrow Transplant
Program, Division of
Hematology/Oncology, Children’s
Hospital of Michigan, and Barbara Ann
Karmanos Cancer Center, Carman and
Ann Adams Department of Pediatrics,
Wayne State University, Detroit, Michigan




Cytometry Part B: Clinical Cytometry
